USFDA approvals: Aurobindo Rivaroxaban launch in Q1FY26

Key developments from Indian drugmakers

Indian pharmaceutical companies reported a series of regulatory updates from the US Food and Drug Administration (USFDA), covering both final approvals and tentative approvals for multiple generic medicines. Aurobindo Pharma said it received final approval to manufacture and market Rivaroxaban Tablets USP, 2.5 mg, and indicated a launch timeline in Q1FY26. In separate disclosures included in the provided material, Aurobindo also announced final approval for Flecainide Acetate Tablets in three strengths. Another update in the same compilation pointed to Zydus Cadila receiving final approval to market Tofacitinib extended-release tablets for rheumatoid arthritis, along with a 180-day exclusivity on a specific strength.

These updates matter for investors because USFDA approvals can open up access to the US generics market, but the pace of commercialisation depends on launch plans, supply readiness, and any patent or exclusivity constraints. The filings also highlight how different products sit at different stages of the US regulatory pathway, from final approval to tentative approval where marketing cannot start.

Aurobindo’s final approval for Rivaroxaban 2.5 mg

Aurobindo Pharma Limited said it received final approval from the USFDA to manufacture and market Rivaroxaban Tablets USP, 2.5 mg. The company stated the product is bioequivalent and therapeutically equivalent to the reference listed drug XARELTO 2.5 mg of Janssen Pharmaceuticals Inc. Aurobindo added that it plans to launch the product in Q1FY26.

Rivaroxaban is used across several clinical settings. As described in the provided text, the medicine is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduce the risk of recurrence of DVT and PE. It is also used for prophylaxis of DVT that may lead to PE in patients undergoing knee or hip replacement surgery.

Alongside the final approval for the 2.5 mg strength, Aurobindo said it also received tentative approval from the USFDA for Rivaroxaban Tablets USP in 10 mg, 15 mg, and 20 mg strengths. Tentative approval typically indicates the application has met key review requirements, but the product cannot be marketed until outstanding issues, such as patents or exclusivities, are resolved.

Aurobindo’s Flecainide approval update

In another regulatory disclosure included in the text, Aurobindo Pharma said it received final USFDA approval to manufacture and market Flecainide Acetate Tablets USP in 50 mg, 100 mg, and 150 mg strengths, referencing ANDA 202821. The update was presented as a formal regulatory filing statement.

While the compiled material does not provide a launch date for Flecainide, the final approval itself indicates Aurobindo can proceed with marketing subject to its own commercial decisions and market conditions. The presence of multiple strengths also suggests potential to address a broader segment of prescribing requirements in the US market, depending on demand patterns.

Zydus Cadila’s Tofacitinib XR approval and exclusivity

The material also states that Zydus Cadila received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis. It further adds that Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and holds 180-day exclusivity on this strength.

The broader prescribing information excerpted in the provided text describes tofacitinib extended-release tablets as Janus kinase (JAK) inhibitors. The indications listed include adult patients with moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS), specifically in patients who have had an inadequate response or intolerance to one or more TNF blockers.

The same extract also lists limitations of use, stating that use in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended for RA, AS, or PsA. It also states that tofacitinib tablets 10 mg twice daily and tofacitinib extended-release tablets 22 mg once daily dosages are not recommended for treatment of RA, PsA, or AS.

Safety and label highlights included in the material

The provided text contains a summary of common adverse reactions and safety risks described for tofacitinib products. The most common adverse reactions for RA, PsA, and AS reported in at least 2% of adult patients treated with tofacitinib tablets monotherapy or in combination with DMARDs were upper respiratory tract infection, nasopharyngitis, diarrhea, and headache.

It also states that patients treated with tofacitinib extended-release tablets are at increased risk for developing serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis, which may lead to hospitalisation or death. Another excerpt notes that, in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer) was observed in patients treated with tofacitinib tablets 5 mg or 10 mg twice a day compared with TNF blockers.

Separately, the text includes a note to report suspected adverse reactions to Aurobindo Pharma USA, Inc. and provides contact details and the FDA MedWatch channel, indicating a pharmacovigilance route referenced in the material.

Patent and litigation context referenced for tofacitinib

The compilation includes content describing patent-related disputes around Pfizer’s Xeljanz (tofacitinib). It states that Pfizer filed a petition in the US District Court for the District of Delaware alleging infringement of two patents related to Xeljanz, connected to Aurobindo’s ANDA filing for tofacitinib tablets in 5 mg and 10 mg strengths. The same material mentions that Pfizer sought to restrain Aurobindo from launching generic versions before patent expiry dates cited as 2023 and 2025.

This context is important because, for certain products, the path from ANDA submission to commercial launch can be shaped by litigation outcomes, settlement terms, or patent expiry timelines. The provided text also includes an example of a separate ANDA (Baricitinib Tablets, 1 mg and 2 mg) described as tentatively approved due to patent issues, noting final approval cannot be granted until specific legal or expiry conditions are met.

Summary table of the reported USFDA updates

Market impact and what investors should track

The immediate market relevance of these updates lies in the regulatory clarity they provide. Aurobindo’s statement that Rivaroxaban 2.5 mg will be launched in Q1FY26 creates a defined near-term milestone for execution. In contrast, tentative approvals for additional Rivaroxaban strengths indicate progress but do not translate into immediate marketing authorisation.

For Zydus, the mention of 180-day exclusivity on Tofacitinib extended-release tablets 22 mg suggests a time-bound window of competitive advantage on that strength, subject to the terms of US generic exclusivity rules. Investors typically track whether a company is a first-to-file ANDA applicant, because that status can influence early-period pricing and market share, although the compiled text does not provide financial estimates.

Conclusion

The disclosures point to continued momentum among Indian drugmakers in expanding US portfolios through ANDA approvals. Aurobindo’s final approval for Rivaroxaban 2.5 mg and its stated Q1FY26 launch plan will be a key near-term operational milestone, while Zydus’ Tofacitinib XR approval and exclusivity claim highlight the role of filing strategy in US generics. The next updates to watch, based on the material, are actual launch execution for Rivaroxaban 2.5 mg and any progression from tentative to final approvals for other strengths where patent constraints may apply.